Time to Buy these ASX Growth Shares is Now

In a market where consistency defines true growth, these ASX listed players continue to deliver innovation, profitability and scale that set them apart from the pack.

CSL Limited (ASX: CSL)

keeps showing why it is one of the top names in global biopharma space.

In FY25, it pulled off steady growth and strong operations again. The company made around US$15.56 billion in revenue, which is about 5% higher than last year. Its NPAT came at US$3.09 billion, a jump of 17%.

 Free cash flow went up 58% to US$2.87 billion and leverage got better at 1.8x EBITDA. CSL also increased its yearly dividend by 11% to US$2.92 per share. 

Going forward, CSL aims to split off CSL Seqirus by FY26 to form a separate vaccine-focused company. It also expects to save around US$500–550 million each year by FY28 from its cost-cutting projects. 

With its strong position in plasma therapies, iron deficiency drugs, and rare disease treatments, plus a solid R&D lineup and rising margins, CSL stays a powerful and stable player in healthcare sector globally.

Cochlear Limited (ASX: COH)

maintained its impressive position in implantable hearing solutions with record numbers in FY25. 
The company’s growth came mainly from new innovations, rising demand and wider global reach. Its sales revenue went up by 4% to about $2.36 billion. The underlying net profit rose 1% to $392 million. 

Cochlear maintained a solid 74% gross margin and ended the year with around $276 million net cash showing good operation control. It also declared a final dividend of $2.15 per share making total dividend $4.30 for the year which is 5% higher than last year.

For FY26, the company expects profit growth between 11 to 17% supported by new launches. Around 12% of revenue was put into R&D. Its growing presence in both developed and developing countries makes it a leading healthcare brand improving hearing and brain health worldwide.

Rio Tinto Limited (ASX: RIO)

had another great quarter in Q3 2025, showing solid performance across its wide range of operations and keeping a disciplined approach to spending.

The company reached record bauxite production of 16.4Mt, up 9% from last year, and kept Pilbara iron ore shipments steady at 84.3Mt, which is 6% higher than Q2.

Copper production went up by 10% YoY to 204kt, helped by the underground ramp up at Oyu Tolgoi. The company’s cash flow is still strong because of better commodity prices and higher efficiency. 

Big projects like Simandou in Guinea and the Rincon Lithium Project in Argentina are moving ahead as planned, and the new low carbon AP60 aluminium smelter in Canada is expected to start running in early 2026. 

Rio Tinto stands out as a solid growth stock giving exposure to iron ore, copper, lithium and aluminium which are all key materials for the world’s energy transition.

Xero Limited (ASX: XRO)

had another strong year in FY25 showing why it’s one of the top SaaS companies for small businesses.
Its operating revenue went up by 23% to around NZ$2.1 billion backed by steady subscriber growth of 6% taking total users to 4.41 million and a 15% rise in ARPU to NZ$45.08. Adjusted EBITDA increased 22% to NZ$641 million and free cash flow jumped 48% to NZ$507 million. Net profit climbed 30% to NZ$227.8 million and gross margin improved to 89% showing better cost control. 

The company ended the year with NZ$683 million in net cash and NZ$2.3 billion total liquidity. For FY26 Xero plans to scale its AI based JAX assistant, grow payments adoption and build more around accounting, payroll and finance tools. 

(Source: Company Reports)